Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Sensitivity of ctDNA equivalent to that of tumor tissue sequencing
Key clinical point: For detection of genomic aberrations in patients with advanced breast cancer, sensitivity of circulating tumor DNA (ctDNA) testing is effectively equivalent to that of tumor tissue sequencing.
Major finding: When plasma and tumor tissue samples were taken within 60 days of one another, sensitivity of ctDNA testing was 98% for digital droplet PCR (ddPCR) and 100% for targeted sequencing.
Study details: The open-label, multicenter plasmaMATCH trial involved more than 1,000 patients with advanced breast cancer.
Disclosures: The investigators disclosed ties with AstraZeneca, Puma Biotechnology, Bio-Rad, and Guardant Health.
Kingston et al. SABCS 2019. Abstract GS3-07.